Aminosalicylic acid

Revision as of 22:05, 25 December 2013 by Gerald Chi (talk | contribs)
Jump to navigation Jump to search
Aminosalicylic Acid
PASER® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Synonyms and keywords: para-aminosalicylic acid, p-aminosalicylic acid or 4-aminosalicylic acid; abbreviated 4-ASA, or PAS

Overview

Aminosalicylic acid is an antibiotic used to treat tuberculosis. It has been use for over forty years in the treatment of inflammatory bowel disease (IBD), where it has shown greater potency in Crohn's disease. It is thought to act via NF-κB (nuclear factor-kappa B) inhibition and free radical scavenging.

Aminosalicylic acid is sold in the United States by Jacobus Pharmaceutical as PASER®.

Mesalazine (5-aminosalicylic acid) is a closely related compound that also has medical uses.

Category

Antimycobacterial

US Brand Names

PASER®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages

Mechanisms of Action

Aminosalicylic acid is an analogue of para-aminobenzoic acid (PABA) and acts as a competitive inhibitor of dihydropteroate synthase 1 (folP1). Its competitive antagonism with PABA is similar to the action of sulfonamides which disrupts biosynthesis in sensitive organisms. Aminosalicylic acid is bacteriostatic against Mycobacterium tuberculosis. It inhibits the onset of bacterial resistance to streptomycin and isoniazid. Other mechanism of action has been postulated to be inhibition of synthesis of the cell wall component, mycobactin, thus reducing iron uptake by M. tuberculosis.

References